Clinical trials: Colorectal Cancer Recurrent
Colon Adenomas
APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence
Experimental and epidemiologic studies have suggested that aspirin intake reduces the risk for colorectal cancer. In the APACC study we randomly assigned 291 patients to daily Aspirin or Placebo for 4 years.
- Trial name
- NCT00224679
- Testing
- Aspirin
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Plasma Biomarkers C-RAC, ICORG 12-27, V1
This is an exploratory, translational, non-interventional and multi-centre clinical study.
- Trial name
- NCT02050737
- Where
- 14 sites in Ireland
- Volunteers
- 109 people
- Sponsor
- Cancer Trials Ireland
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
Rectal Neoplasms
Endoscopic Submucosal Dissection vs Local Laparoscopic Surgical Resection (TAMIS/TEO) in Early Rectal Neoplasias
A multicenter non-inferiority randomized clinical trial to compare Endoscopic treatment (ESD) and Minimally Invasive Laparoscopic Local Surgical Treatment (TAMIS or TEO) for early rectal neoplastic lesions (adenoma \& T1CRC)…
- Trial name
- DSETAMIS2018 (NCT03959839)
- Testing
- ESD, TAMIS, TEO
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Dr. Alberto Herreros de Tejada Echanojáuregui
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039273
- Testing
- panitumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rectal Cancer, Recurrent Rectal Cancer
SGM-101 in Locally Advanced and Recurrent Rectal Cancer
Near-infrared fluorescence-guided oncologic surgery (EGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness, which can…
- Trial name
- SGM-LARRC (NCT04642924)
- Testing
- SGM-101
- Where
- 4 sites in Netherlands
- Volunteers
- 203 people
- Sponsor
- Leiden University Medical Center
Neoplasms, Adenocarcinoma
Beyond TME Origins
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available.
- Conditions
- Neoplasms, Adenocarcinoma, Carcinoma
- Trial name
- NCT02292641
- Testing
- New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
- Where
- 4 sites in Norway, United Kingdom
- Volunteers
- 383 people
- Sponsor
- Imperial College London
Colorectal Cancer
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- OMEGA (NCT00467142)
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Institut Bergonié
Colorectal Cancer
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00608595
- Testing
- celecoxib, gene expression analysis, protein expression analysis
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Neoplasms
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer
This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group.
- Trial name
- NCT03923335
- Testing
- DNA methylation detection
- Where
- China
- Volunteers
- 287 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Colorectal Cancer
Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or…
- Trial name
- NCT00002933
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD
Liver Metastases, Colorectal Cancer
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant…
- Conditions
- Liver Metastases, Colorectal Cancer, Surgery, Circulating Tumor DNA
- Trial name
- NCT06404593
- Testing
- Blood sampling
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer, Head and Neck Cancer
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
RATIONALE: Diagnostic procedures using boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) to detect the presence of boron in tumor cells may help determine whether patients who have thyroid cancer, head…
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Metastatic Cancer
- Trial name
- NCT00062348
- Testing
- boronophenylalanine-fructose complex, sodium borocaptate, conventional surgery
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- FOLFERA (NCT01205711)
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Cardiff University
Colorectal Cancer, Esophageal Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00025532
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Sponsor
- University of California, San Francisco
Recurrent or Metastatic Colorectal Cancer
A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers
To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.
- Trial name
- NCT00155558
- Testing
- 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005076
- Testing
- cetuximab, irinotecan hydrochloride
- Volunteers
- 110 people
- Sponsor
- University of Alabama at Birmingham